The diabetes assignment
SUSTAIN and first US approvals · 2016–2019
Could a diabetes medicine do more than lower glucose?
Subject One finds a wall covered in thousands of tiny marks. He adds a large gold star for himself. Doctide replaces it with a mark the same size as the others. “That feels personal.” “Exactly,” says Doctide. “Now we have to see past one person.”
What changes here
The diabetes program examined cardiovascular outcomes as well as glucose control. Eye-related complications also required attention. [1]
Read the study details & dates
The cardiovascular safety question
SUSTAIN-6 studied 3,297 people with type 2 diabetes and high cardiovascular risk. Major cardiovascular events occurred in 6.6% with semaglutide and 8.9% with placebo; the trial met its prespecified noninferiority goal. Retinopathy complications were more frequent, and gastrointestinal effects led to more discontinuations. [1]
Glucose control in Phase 3
SUSTAIN-1 provided Phase 3 evidence for semaglutide as diabetes monotherapy compared with placebo. [2]
Two product milestones
Ozempic received initial US approval for type 2 diabetes in 2017. Oral semaglutide, Rybelsus, followed in 2019. A different formulation required its own development and regulatory review. [3] [4]
What this does not establish
A favorable average result does not erase a safety signal. SUSTAIN-6’s eye-related finding belongs beside its cardiovascular result, not in an invisible footnote.
Original sources
- SUSTAIN-6 primary publication (2016)
- SUSTAIN-1 primary publication (2017)
- FDA regulatory record for Ozempic’s approval date
- FDA Rybelsus approval letter (2019)
Sources reviewed 2026-10-11. Study and publication dates are stated separately where known.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story